In HCC, ARID1A deficiency has been observed to be associated with HCC carcinogenesis by activating the angiopoietin-2 angiogenesis pathway; sorafenib has been shown to suppress this specific pathway and ARID1A deficiency may confer sensitivity to treatment with sorafenib [28]. This evidence concerns the gene ARID1A and hepatocellular carcinoma.